Clinical Trial Update: Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®) [Phase 3]

View source ↗

Summary

Pfizer completed a Phase 3 safety and immunogenicity study of NeisVac-C (meningococcal serogroup C conjugate vaccine) in toddlers previously immunized with PCV7…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease
• Meningococcal Disease

Drugs mentioned

• NeisVac-C (Meningococcal conjugate vaccine against Neisseria meningitidis group C)

Snippet

Sponsor: Pfizer | Conditions: Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD) | Phase 3 | Status: COMPLETED